Alithea Genomics co-founder and CSO Daniel Alpern explained why bringing transcriptomics to screening scale requires rethinking the workflow in a short clip from the Drug Discovery World webinar.
Public source
Publisher name
Public post
RNA-seq can provide a remarkably rich view of how cells respond to a perturbation. So why has it historically played such a limited role in large-scale screening? The an…
Company
Alithea Genomics
Large scale RNA sequencing. Made easy.
- Industry
- Biotechnology
- Location
- Epalinges, CH
- Company size
- 11–50 employees
About Alithea Genomics
RNA sequencing at scale.
See moreLatest activity
Latest activity from Alithea Genomics
2 signals
Discover more
Similar signals
Similar public activity from other companies.
Presence & Recognition
PacBio
PacBio hosted a webinar featuring two leading researchers discussing how long-read multiomics is advancing rare disease diagnostics, uncovering neurodegenerative mechanisms, and leveraging AI for therapeutic discovery.
Presence & Recognition
BioAgilytix
BioAgilytix hosted an on-demand webinar featuring scientists from BioAgilytix, Moderna, and Eurofins discussing developing RT-qPCR assays for LNP-mRNA drug products.
Presence & Recognition
Sygnature Discovery
Sygnature Discovery's Gavin Milne will join guest speaker Prashant Desai (Genentech) and Optibrium CEO Matthew Segall for the upcoming webinar on metabolism in discovery.
Presence & Recognition
Domainex
Domainex hosted a webinar featuring Jim Reid discussing TRPML3 and membrane protein activity.
Presence & Recognition
Aliri Bioanalysis